Latest updates for Ivncx
Fresh curated links around IVNCX are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
- Nomura Global Growth Fund Q2 2026 Commentary
- INVIVYD
- NIE: This Convertible CEF Is Worth A Test Drive
Post angles to try
Share the most useful takeaway for your audience.
Turn one article into a quick practical checklist.
Ask your audience how this shift affects their work.
Fresh articles and ideas
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
cafepharma.com
/1 month ago
INVIVYD
INVIVYD Anonymous (not verified) Tue, 08/04/2026 - 21:28 field_thread_url https://cafepharma.com/boards/threads/invivyd.703943/ board na...
seekingalpha.com
/3 weeks ago
National CineMedia Diversifies Away From Cinema With Transformative Acquisition
seekingalpha.com
/1 week ago
Nova: AI's Metrology Tollbooth Is Becoming A Multi-Engine Compounder
seekingalpha.com
/1 week ago
NTG Clarity Networks Inc. (NCI:CA) Q2 2026 Earnings Call Transcript
seekingalpha.com
/2 weeks ago
RNIN: Outperforming SMID Play With A GARP Tilt Worth Shortlisting
fool.com
/1 month ago
INmune Bio (INMB) Q2 2026 Earnings Call Transcript
Ebstracel nears UK filing as XPro shows Alzheimer's biomarker progress.
seekingalpha.com
/4 weeks ago
Ncmi outlines Captivate deal financing with ~3.9x net leverage at close and pauses dividend
seekingalpha.com
/1 month ago
I3 Verticals signals FY2027 mid-single-digit growth while targeting 100 to 200 bps margin expansion
seekingalpha.com
/2 days ago
Voya Infrastructure, Industrials And Materials Fund Q2 2026 Commentary
fool.com
/1 month ago
What This Immunome Sale Means a Day Before a Big FDA Milestone
Barchas maintains 211,763 residual shares through direct and indirect holdings following execution under a Rule 10b5-1 trading plan adopted in March 2026.
financialsamurai.com
/1 month ago
VCX NAV Estimate: What Fundrise’s Innovation Fund Is Really Worth
When Fundrise's Innovation Fund (VCX) listed on the NYSE on March 19, 2026, its net asset value was $18.97 a share. Within days, retail investors momentarily bid the price above $4...
seekingalpha.com
/3 weeks ago
Nebius: Avoid Chasing, Even If You Missed The Ride (Rating Downgrade)
fool.com
/1 month ago
Innoviz (INVZ) Q2 2026 Earnings Call Transcript
Record revenue and defense market entry signal a strategic shift for LiDAR maker Innoviz.
seekingalpha.com
/2 weeks ago
Voya Strategic Income Opportunities Fund Q2 2026 Commentary
seekingalpha.com
/2 weeks ago
U.S. IPO Weekly Recap: Lyntris And First Breach Lead A Defense-Heavy Week
newswire.com
/1 month ago
NexTel Medical Corp. Advances Veterinary Oncology Strategy with Rollout of Early-Stage Cancer Screening for Companion An...
Company targets a growing $1.2B+ North American pet oncology market leveraging proprietary exosome-based diagnostic technologies.
Turn fresh research into a full content calendar
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.
Sources covering Ivncx
seekingalpha.com
Recent coverage from public sources
Public source
cafepharma.com
Recent coverage from public sources
Public source
seekingalpha.com
Recent coverage from public sources
Public source
seekingalpha.com
Recent coverage from public sources
Public source
financialsamurai.com
Recent coverage from public sources
Public source
fool.com
Recent coverage from public sources
Public source